Nasdaq · CIK 0001873835
IMMX Immix Biopharma, Inc.
Insider trading from SEC Form 4. Last filing May 29, 2026. Close $9.25 on Oct 12, 2026, +273% from the 52-week low and -36% from the high.
In brief
Immix Biopharma, Inc. (IMMX) has 26 SEC Form 4 filings on file from 9 insiders, the latest filed on May 29, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
8 open-market trades have been scored at IMMX. The newest: Gabriel S Morris (CFO) bought $5,067 of stock on Dec 10, 2025, filed Dec 10, 2025, scored 30 (weak). The largest of the 8 shown: Jason Hsu (director) bought $267k on Dec 8, 2023, scored 31 (weak). 2 insiders bought within 14 days of each other around Dec 10, 2025.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Immix Biopharma, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | Gabriel S Morris CFO buy | $5,067 770 shares | +0% | +395% from low0% from high | |
| 33Weak | Ilya M Rachman CEO and Chairman buy | $4,976 746 shares | +0% | +395% from low0% from high | |
| 38Weak | Gabriel S Morris CFO buy | $5,122 2,600 shares | +1% | +49% from low-33% from high | |
| 36Weak | Ilya M Rachman CEO and Chairman buy | $5,050 2,500 shares | +0% | +46% from low-34% from high | |
| 25Weak | Gabriel S Morris CFO buy | $5,071 2,225 shares | +1% | +78% from low-8% from high | |
| 28Weak | Ilya M Rachman CEO and Chairman buy | $4,999 2,178 shares | +0% | +78% from low-8% from high | |
| 28Weak | Jason Hsu director buy | $104k 47,700 shares | +6% | - | |
| 31Weak | Jason Hsu director buy | $267k 56,000 shares | +7% | +353% from low-9% from high |
Transactions
Every row filed, 38 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | Helen C. Adams director | AGrant or award Common Stock | +6,250 | $0.00 | $0 | 181,004 | May 29, 2026 |
| May 22, 2026 | Jane Buchan director | AGrant or award Common Stock | +6,250 | $0.00 | $0 | 28,705 | May 29, 2026 |
| May 22, 2026 | Carey Ng director | AGrant or award Common Stock | +6,250 | $0.00 | $0 | 26,250 | May 29, 2026 |
| May 22, 2026 | Nancy T Chang director | AGrant or award Common Stock | +6,250 | $0.00 | $0 | 428,190 | May 29, 2026 |
| May 22, 2026 | Gabriel S Morris CFO, President | AGrant or award Stock Option (Right to Buy)derivative | +500,000 | $0.00 | $0 | 500,000 | May 29, 2026 |
| May 22, 2026 | Yekaterina Chudnovsky director | AGrant or award Common Stock | +6,250 | $0.00 | $0 | 6,250 | May 29, 2026 |
| May 22, 2026 | Magda Marquet director | AGrant or award Common Stock | +6,250 | $0.00 | $0 | 52,342 | May 29, 2026 |
| May 22, 2026 | Jason Hsu director | AGrant or award Common Stock | +6,250 | $0.00 | $0 | 899,250 | May 29, 2026 |
| May 22, 2026 | Ilya M Rachman CEO and Chairman | AGrant or award Stock Option (Right to Buy)derivative | +500,000 | $0.00 | $0 | 500,000 | May 29, 2026 |
| May 22, 2026 | Helen C. Adams director | AGrant or award Stock Option (Right to Buy)derivative | +12,500 | $0.00 | $0 | 12,500 | May 29, 2026 |
| May 22, 2026 | Jane Buchan director | AGrant or award Stock Option (Right to Buy)derivative | +12,500 | $0.00 | $0 | 12,500 | May 29, 2026 |
| May 22, 2026 | Yekaterina Chudnovsky director | AGrant or award Stock Option (Right to Buy)derivative | +12,500 | $0.00 | $0 | 12,500 | May 29, 2026 |
| May 22, 2026 | Magda Marquet director | AGrant or award Stock Option (Right to Buy)derivative | +12,500 | $0.00 | $0 | 12,500 | May 29, 2026 |
| May 22, 2026 | Nancy T Chang director | AGrant or award Stock Option (Right to Buy)derivative | +12,500 | $0.00 | $0 | 12,500 | May 29, 2026 |
| May 22, 2026 | Carey Ng director | AGrant or award Stock Option (Right to Buy)derivative | +12,500 | $0.00 | $0 | 12,500 | May 29, 2026 |
| May 22, 2026 | Jason Hsu director | AGrant or award Stock Option (Right to Buy)derivative | +12,500 | $0.00 | $0 | 12,500 | May 29, 2026 |
| Nov 21, 2025 | Nancy T Chang director | AGrant or award Stock Option (Right to Buy)derivative | +39,643 | $0.00 | $0 | 39,643 | Dec 11, 2025 |
| Dec 10, 2025 | Ilya M Rachman CEO and Chairman | POpen-market purchase Common Stock | +746 | $6.67 | $4,976 | 1,141,683 | Dec 10, 2025 |
| Dec 8, 2025 | Gabriel S Morris CFO | XIn-the-money exercise Common Stockindirect: See footnote | +156,000 | $0.80 | $125k | 426,844 | Dec 10, 2025 |
| Dec 10, 2025 | Gabriel S Morris CFO | POpen-market purchase Common Stock | +770 | $6.58 | $5,067 | 291,429 | Dec 10, 2025 |
| Dec 8, 2025 | Gabriel S Morris CFO | XIn-the-money exercise Warrants (right to purchase)derivativeindirect: See footnote | -96,000 | $0.00 | $0 | 0 | Dec 10, 2025 |
| Dec 8, 2025 | Gabriel S Morris CFO | XIn-the-money exercise Warrants (right to purchase)derivativeindirect: See footnote | -60,000 | $0.00 | $0 | 0 | Dec 10, 2025 |
| Sep 17, 2025 | Ilya M Rachman CEO and Chairman | POpen-market purchase Common Stock | +2,500 | $2.02 | $5,050 | 1,140,937 | Sep 17, 2025 |
| Sep 16, 2025 | Gabriel S Morris CFO | POpen-market purchase Common Stock | +2,600 | $1.97 | $5,122 | 290,659 | Sep 17, 2025 |
| Jun 20, 2025 | Helen C. Adams director | AGrant or award Stock Option (Right to Buy)derivative | +33,000 | $0.00 | $0 | 33,000 | Jun 23, 2025 |
| Jun 20, 2025 | Jane Buchan director | AGrant or award Stock Option (Right to Buy)derivative | +33,000 | $0.00 | $0 | 33,000 | Jun 23, 2025 |
| Jun 20, 2025 | Yekaterina Chudnovsky director, owner | AGrant or award Stock Option (Right to Buy)derivative | +33,000 | $0.00 | $0 | 33,000 | Jun 23, 2025 |
| Jun 20, 2025 | Ilya M Rachman CEO and Chairman | AGrant or award Stock Option (Right to Buy)derivative | +340,000 | $0.00 | $0 | 340,000 | Jun 23, 2025 |
| Jun 20, 2025 | Magda Marquet director | AGrant or award Stock Option (Right to Buy)derivative | +33,000 | $0.00 | $0 | 33,000 | Jun 23, 2025 |
| Jun 20, 2025 | Carey Ng director | AGrant or award Stock Option (Right to Buy)derivative | +33,000 | $0.00 | $0 | 33,000 | Jun 23, 2025 |
| Jun 20, 2025 | Gabriel S Morris CFO | AGrant or award Stock Option (Right to Buy)derivative | +340,000 | $0.00 | $0 | 340,000 | Jun 23, 2025 |
| Jun 20, 2025 | Jason Hsu director | AGrant or award Stock Option (Right to Buy)derivative | +33,000 | $0.00 | $0 | 33,000 | Jun 23, 2025 |
| Jun 18, 2025 | Gabriel S Morris CFO | POpen-market purchase Common Stock | +2,225 | $2.28 | $5,071 | 288,059 | Jun 20, 2025 |
| Jun 18, 2025 | Ilya M Rachman CEO and Chairman | POpen-market purchase Common Stock | +2,178 | $2.30 | $4,999 | 1,138,437 | Jun 20, 2025 |
| Dec 20, 2024 | Jason Hsu director | POpen-market purchase Common Stock | +7,700 | $2.17 | $17k | 853,000 | Dec 26, 2024 |
| Dec 23, 2024 | Jason Hsu director | POpen-market purchase Common Stock | +40,000 | $2.19 | $88k | 893,000 | Dec 26, 2024 |
| Dec 8, 2023 | Jason Hsu director | POpen-market purchase Common Stock | +25,000 | $4.88 | $122k | 782,000 | Dec 12, 2023 |
| Dec 11, 2023 | Jason Hsu director | POpen-market purchase Common Stock | +31,000 | $4.67 | $145k | 813,000 | Dec 12, 2023 |
Insiders
Everyone who has filed a Form 4 here.
- Helen C. Adamsdirector
- Jane Buchandirector
- Nancy T Changdirector, owner
- Yekaterina Chudnovskydirector, owner
- Jason Hsudirector
- Magda Marquetdirector
- Gabriel S MorrisCFO, President
- Carey Ngdirector
- Ilya M RachmanCEO and Chairman
Questions about IMMX
Answered from the filings on this page, as of the latest one.
Are insiders buying IMMX?
No. In the last 90 days no insider at Immix Biopharma, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade IMMX on the open market?
Gabriel S Morris (CFO) bought $5,067 of IMMX on Dec 10, 2025 and filed the Form 4 on Dec 10, 2025. InsiderTell scored 30 (weak), with 2 insiders on the same side within 14 days.
How many insiders file Form 4 at Immix Biopharma, Inc.?
9 people have filed a Form 4 at Immix Biopharma, Inc., among them Helen C. Adams (director), Jane Buchan (director), Nancy T Chang (director and 10% owner). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.